Gyre Therapeutics, Inc. (NasdaqCM: GYRE)
Health Care · Biotechnology · US
$6.76
-4.92% today · -3.1% 1Y
Gyre Therapeutics, Inc. (NasdaqCM: GYRE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $753.90M and employs 625 people.
Over the last twelve months the share price has lost 3.1%, trading between 5.44 and 9.42.
Tweenvest scores Gyre Therapeutics, Inc. across four factors: quality 84/100, value 68/100. Its strongest factor is quality.
GYRE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $753.90M
- Revenue (TTM)
- $109.82M
- P/E
- —
- EPS
- -0.22
- Dividend yield
- —
- Beta (5Y)
- 4.74
- 52-week high
- $9.42
- 52-week low
- $5.44
- Avg volume (3M)
- —
- Shares outstanding
- 106.03M
- Employees
- 625
- Next earnings
- —
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
- ISIN
- US4037831033
- Founded
- 2002
- Listed since
- Apr 12, 2006
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Geron CorporationNasdaqGS: GERN | $783.82M | $1.22 | +1.67% |
| Candel Therapeutics, Inc.NasdaqGM: CADL | $778.96M | $9.66 | -5.11% |
| Annexon, Inc.NasdaqGS: ANNX | $758.32M | $4.00 | -0.25% |
| Getein Biotech, IncSHSE: 603387 | $755.75M | CN¥10.01 | +1.93% |
| JS Link, Inc.KOSDAQ: A127120 | $753.50M | ₩29,200.00 | -8.18% |
| Shenzhen Weiguang Biological Products Co., Ltd.SZSE: 002880 | $751.63M | CN¥22.23 | +3.35% |
| Qurient Co., Ltd.KOSDAQ: A115180 | $748.15M | ₩24,750.00 | +9.51% |
| ChemPartner PharmaTech Co.,Ltd.SZSE: 300149 | $745.31M | CN¥9.90 | +2.59% |
Figures last refreshed Oct 4, 2026.